ScoreWhy is Shanxi C&Y Pharmaceutical Group Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 2.56%
- The company has been able to generate a Return on Capital Employed (avg) of 2.56% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of -1.20% and Operating profit at 21.09% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 7.73% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of -1.20% and Operating profit at 21.09% over the last 5 years
- NET PROFIT(Q) At CNY 3.34 MM has Fallen at -61.31%
- DEBTORS TURNOVER RATIO(HY) Lowest at 4 times
- INTEREST(Q) At CNY 5.34 MM has Grown at 33.28%
4
With ROE of 12.47%, it has a very expensive valuation with a 2.84 Price to Book Value
- Over the past year, while the stock has generated a return of -9.67%, its profits have fallen by -20.4%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Shanxi C&Y Pharmaceutical Group Co., Ltd. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Shanxi C&Y Pharmaceutical Group Co., Ltd.
-8.87%
0.16
46.43%
China Shanghai Composite
21.43%
1.73
13.79%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-1.20%
EBIT Growth (5y)
21.09%
EBIT to Interest (avg)
-0.09
Debt to EBITDA (avg)
9.89
Net Debt to Equity (avg)
1.37
Sales to Capital Employed (avg)
0.95
Tax Ratio
10.33%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.56%
ROE (avg)
7.73%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
2.84
EV to EBIT
17.57
EV to EBITDA
13.28
EV to Capital Employed
1.94
EV to Sales
1.93
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
11.07%
ROE (Latest)
12.47%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend9What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY 113.96 MM
NET PROFIT(HY)
At CNY 15.57 MM has Grown at 84.72%
RAW MATERIAL COST(Y)
Fallen by -3.71% (YoY
-19What is not working for the Company
NET PROFIT(Q)
At CNY 3.34 MM has Fallen at -61.31%
DEBTORS TURNOVER RATIO(HY)
Lowest at 4 times
INTEREST(Q)
At CNY 5.34 MM has Grown at 33.28%
INTEREST COVERAGE RATIO(Q)
Lowest at 167.81
INVENTORY TURNOVER RATIO(HY)
Lowest at 2.06 times
NET SALES(Q)
Lowest at CNY 173.8 MM
OPERATING PROFIT(Q)
Lowest at CNY 8.96 MM
OPERATING PROFIT MARGIN(Q)
Lowest at 5.15 %
PRE-TAX PROFIT(Q)
Lowest at CNY 12.59 MM
Here's what is working for Shanxi C&Y Pharmaceutical Group Co., Ltd.
Operating Cash Flow
Highest at CNY 113.96 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Raw Material Cost
Fallen by -3.71% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Shanxi C&Y Pharmaceutical Group Co., Ltd.
Net Sales
At CNY 173.8 MM has Fallen at -20.16%
over average net sales of the previous four periods of CNY 217.7 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (CNY MM)
Net Profit
At CNY 3.34 MM has Fallen at -61.31%
over average net sales of the previous four periods of CNY 8.64 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (CNY MM)
Interest
At CNY 5.34 MM has Grown at 33.28%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Interest Coverage Ratio
Lowest at 167.81
in the last five periodsMOJO Watch
The company's ability to manage interest payments is deteriorating
Operating Profit to Interest
Pre-Tax Profit
At CNY 12.59 MM has Fallen at -52.59%
over average net sales of the previous four periods of CNY 26.55 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (CNY MM)
Debtors Turnover Ratio
Lowest at 4 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Net Sales
Lowest at CNY 173.8 MM
in the last five periodsMOJO Watch
Near term sales trend is negative
Net Sales (CNY MM)
Operating Profit
Lowest at CNY 8.96 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (CNY MM)
Operating Profit Margin
Lowest at 5.15 %
in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales
Pre-Tax Profit
Lowest at CNY 12.59 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (CNY MM)
Inventory Turnover Ratio
Lowest at 2.06 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
